<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077657</url>
  </required_header>
  <id_info>
    <org_study_id>PVP012</org_study_id>
    <nct_id>NCT05077657</nct_id>
  </id_info>
  <brief_title>Safe Surveillance of PCI Under Mechanical Circulatory Support With the Saranas Early Bird Bleed Monitoring System</brief_title>
  <acronym>SAFE-MCS</acronym>
  <official_title>Safe Surveillance of PCI Under Mechanical Circulatory Support With the Saranas Early Bird Bleed Monitoring System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saranas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Proxima Clinical Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Saranas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the safety of complex high-risk Percutaneous&#xD;
      Coronary Intervention (PCI) using Mechanical Circulatory Support (MCS) and surveillance with&#xD;
      the Saranas Early Bird Bleed Monitoring System (EBBMS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate that patients undergoing complex high-risk PCI using MCS and surveillance with&#xD;
      the Saranas Early Bird Bleed Monitoring System will have relative incidence rate reduction of&#xD;
      access site related BARC type III or V bleeding. An optimal outcome will estimate a 95%&#xD;
      confidence interval for a reduction in access-site related bleeding rate when using MCS with&#xD;
      the Saranas Saranas Early Bird Bleed Monitoring System in high-risk PCI patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of access site related BARC type III or V bleeding</measure>
    <time_frame>Within 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of activation of each Saranas Early Bird level 1, 2 and 3 indicator</measure>
    <time_frame>Within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all BARC type III or V bleeding</measure>
    <time_frame>Within 24 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Access site related bleeding complications</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Access site related vascular complications</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Access site related blood transfusions</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-access site related bleeding complications</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-access site related vascular complications</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-access site related blood transfusions</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>All blood transfusions</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin drop</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Device and procedure-related adverse events</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Serious adverse device effects</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">265</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Single-Arm</arm_group_label>
    <description>This is a multi-center, single arm, open-label study to evaluate the safety of complex high-risk PCI using Impella and surveillance with the Saranas Early Bird Bleed Monitoring System (EBBMS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Early Bird® Bleed Monitoring System</intervention_name>
    <description>The Early Bird Bleed Monitoring System is used in endovascular procedures to monitor and detect internal bleeding complications in real-time.</description>
    <arm_group_label>Single-Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Impella®</intervention_name>
    <description>Impella is an FDA-approved percutaneous heart pump indicated for patients with severe coronary artery disease requiring high-risk PCI.</description>
    <arm_group_label>Single-Arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing complex high-risk percutaneous coronary intervention (PCI) with&#xD;
        mechanical circulatory support (MCS) via Impella® and transfemoral arterial approach will&#xD;
        be enrolled. The Saranas Early Bird Bleed Monitoring System will be used in the ipsilateral&#xD;
        femoral vein to monitor bleeding events after MCS removal.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  Planned complex high-risk PCI using MCS with Impella from a femoral access and use of&#xD;
             Saranas Early Bird Bleed Monitoring System&#xD;
&#xD;
          -  The study patient has been informed of the nature of the study, agrees to its&#xD;
             provisions, and has provided written informed consent as approved by the institutional&#xD;
             review board of the respective clinical site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absolute contraindications or allergy to iodinated contrast that cannot be adequately&#xD;
             treated with pre-medication&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  Incapacity to access safely femoral artery or femoral vein&#xD;
&#xD;
          -  Significant femoral, iliac, abdominal, or thoracic aortic disease which precludes&#xD;
             placement of MCS&#xD;
&#xD;
          -  Anemia (Hgb &lt;9 g/dL), thrombocytopenia (Plt &lt;50,000 cell/mL), history of bleeding&#xD;
             diathesis or coagulopathy, or hypercoagulable states&#xD;
&#xD;
          -  Active infection not controlled with antibiotic therapy&#xD;
&#xD;
          -  Currently pregnant or women of child-bearing potential without documented negative&#xD;
             pregnancy test&#xD;
&#xD;
          -  Estimated life expectancy &lt; 24 hours&#xD;
&#xD;
          -  Patient is in cardiogenic shock at the time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mir Basir, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Généreux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gagnon Cardiovascular Institute - Morristown Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zaffer Syed</last_name>
    <phone>713-357-1049</phone>
    <email>zaffer@saranas.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia Walsh</last_name>
    <email>julia@saranas.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

